# US 2026/0218127 A1 · Methods for the production of human melanocytes from pluripotent stem cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218127 A1
- Document ID: US20260218127A1
- Status: Published application
- Kind: A1
- Application number: 19/145,640
- Filed: 2023-12-29
- Published: 2026-07-30
- Earliest claimed: 2023-01-04
- Assignees: Centre D'Etude Des Cellules Souches (Cecs); Universite D'Evry Val D'Essonne; Institut National de la Sante et de la Recherche Medicale
- Applicants: Centre D'Etude Des Cellules Souches (Cecs); Universite D'Evry Val D'Essonne; Institut National De La Santé Et De La Recherche MéDicale
- Inventors: Manoubia SAIDANI; Jennifer ALLOUCHE; Christine BALDESCHI
- Web page: https://patentgrep.com/patent/US20260218127A1

## CPC

- C12N 5/0626: {Melanocytes}
- A61K 35/36: Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells (islets of Langerhans A61K35/39)
- C12N 2500/38: Vitamins
- C12N 2501/125: Stem cell factor [SCF], c-kit ligand [KL]
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2501/365: Endothelin
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2503/02: Drug screening
- C12N 2506/02: from embryonic cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2513/00: 3D culture
- C12N 2533/54: Collagen; Gelatin
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention pertains to in vitro methods for obtaining a population of mature and functional human melanocytes from human pluripotent stem cells (hPSC) and to uses of said population. The method according to the present invention comprises a differentiation step wherein neural crest cells are cultured in presence of a GSK3 inhibitor such as CHIR99021 or WNT3A, BMP4, AA, SCF and EDN3.

## Claims

### Claim 1

An in vitro method for obtaining a population of human melanocytes, wherein said method comprises a differentiation step wherein neural crest cells are cultured in presence of a Glycogen Synthase Kinase 3 (GSK3) inhibitor such as CHIR99021 or Wingless-type family member 3A WNT3a, Bone Morphogenic Protein 4 (BMP4), Ascorbic Acid (AA), Stem Cell Factor (SCF) and Endothelin 3 (EDN3).

### Claim 2 (depends on 1)

The method according to claim 1, wherein said method comprises the following steps:
a) an induction step wherein human pluripotent stem cells are cultured in a neural medium to obtain neural crest cells;
b) a differentiation step wherein the neural crest cells obtained in step a) are cultured in presence of a GSK3 inhibitor such as CHIR99021 or WNT3a, BMP4, AA, SCF and EDN3 to obtain melanocyte precursors;
c) a maturation step wherein the melanocyte precursors obtained in step b) are cultured in presence of at least one agent stimulating the maturation of melanocytes to obtain mature human melanocytes; and
d) an amplification step wherein the melanocytes obtained in step c) are cultured on a medium suitable for melanocyte culture to obtain a population of human melanocytes.

### Claim 3 (depends on 2)

The method according to claim 2, wherein step a) is carried over 3 to 7 days.

### Claim 4 (depends on 2)

The method according to claim 2, wherein said method further comprises a step b′), wherein the melanocyte precursors obtained in step b) are enzymatically sorted prior to step c).

### Claim 5 (depends on 2)

The method according to claim 2, wherein said agent stimulating the maturation of melanocytes is an activator of the cAMP pathway such as forskolin.

### Claim 6 (depends on 2)

The method according to claim 2, wherein said method is carried out on a 2D cell culture environment.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said human pluripotent stem cells are seeded at a concentration of 20 000 to 40 000 cells per cm2.

### Claim 8 (depends on 6)

The method according to claim 6, wherein said neural medium comprises CHIR99021 or WNT3A.

### Claim 9 (depends on 6)

The method according to claim 6, wherein said method further comprises a step a′), wherein the neural crest cells obtained in step a) are enzymatically sorted prior to step b)

### Claim 10 (depends on 6)

The method according to claim 6, wherein step b) is carried over 10 to 15 days.

### Claim 11 (depends on 6)

The method according to claim 6, wherein said method comprises the following steps:
a) culturing human pluripotent stem cells at a concentration of 20 000 to 40 000 cells per cm2 on a neural culture medium comprising CHIR99021 during 3 to 7 days to obtain neural crest cells;
a′) enzymatically sorting the neural crest cells obtained in step a);
b) culturing the neural crest cells sorted in step a′) on the neural culture medium further comprising BMP4, AA, SCF and EDN3 during 10 to 15 days to obtain melanocyte precursors;
b′) enzymatically sorting the melanocyte precursors obtained in step b);
c) culturing the melanocyte precursors sorted in step b′) on the culture medium used in step b) further comprising forskolin and passaging the cells once or twice to obtain mature human melanocytes; and
d) culturing the melanocytes obtained in step c) on a medium suitable for melanocyte culture during at least 20 passages to allow for their proliferation and obtain a population of human melanocytes.

### Claim 12 (depends on 2)

The method according to claim 2, wherein said method is carried out in a 3D cell culture environment.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said 3D cell culture environment is a 96-well plate, and wherein said human pluripotent stem cells are seeded at a concentration of 8 000 to 12 000 cells per well.

### Claim 14 (depends on 12)

The method according to claim 12, wherein said neural medium comprises CHIR99021 or WNT3a, LDN193189 and SB431542.

### Claim 15 (depends on 12)

The method according to claim 12, wherein step b) is carried over 20 to 28 days.

### Claim 16 (depends on 6)

The method according to claim 6, wherein said method comprises the following steps:
a) culturing human pluripotent stem cells on a 96-well plate at a concentration of 8 000 to 12 cells per well in a neural culture medium comprising CHIR99021, LDN193189 and SB431542 during 3 to 7 days to form embryoid bodies (EB) containing neural crest cells;
b) plating the embryoid bodies obtained in step in step a) to allow the neural crest cells to exit said embryoid bodies and then culturing during 20 to 25 days said neural crest cells in a medium suitable for melanocyte culture further comprising CHIR99021, BMP4, AA, SCF and EDN3 to obtain melanocyte precursors;
b′) enzymatically sorting the melanocyte precursors obtained in step b);
c) culturing the melanocyte precursors sorted in step b′) on the culture medium used in step b) further comprising forskolin to obtain mature human melanocytes; and
d) culturing the melanocytes obtained in step c) on a medium suitable for melanocyte culture during at least 20 passages to allow for their proliferation and obtain a population of human melanocytes.

### Claim 17 (depends on 1)

A population of human melanocytes, wherein said population is obtainable by means of the method according to claim 1.

### Claim 18 (depends on 17)

The population of human melanocytes according to claim 17 for use in the treatment of a skin pigmentation disorder, such as vitiligo, or in the treatment of a skin lesion.

### Claim 19 (depends on 17)

Use of the population of human melanocytes according to claim 17 as a cellular model.

### Claim 20 (depends on 17)

A method for screening candidate cosmetic or therapeutic compounds, wherein said method comprises the following steps:
i) Culturing the population of human melanocytes according to claim 17 in presence of a candidate compound;
ii) Assaying the effects of said candidate therapeutic compound on said population of human melanocytes; and
iii) Selecting said compound based on said effects on the population of human melanocytes.
